APLM logo

APOLLOMICS INC

APLMNASDAQ
πŸ† #4136 by market capEarnings Sep 24US Equity
$17.68β–Ό $0.47 (βˆ’2.64%)
Live
1hβ€”
24hβ–Ό 2.6%
7dβ–² 1.1%
14dβ–² 1.1%
30dβ–² 4.3%
1yβ–² 191.7%
🏦Market Cap
$39M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+4192.9%
High Growth
πŸ“ŠGross Margin
100.0%
High
πŸ’΅FCF Margin
-122.0%
Thin
βš–οΈP/S Ratio
4.6x
Fair
Otter Score
61
Fair

Trading Snapshot

Day Range
$17.48 – $17.87
52-Week Range
$3.66 – $42.12
Volume
$2.66B
Avg Volume
$1.96B
Shares Outstanding
2.2M
Next Earnings
Sep 18, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
-2.3
P/S Ratio
4.6x
EPS (TTM)
$-25.98
Dividend Yield
0.00%

Why Investors Own APLM

  • βœ“High-growth profile β€” revenue up -9.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 47% gross margin and 27% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$9Mβ–Ό βˆ’5.8% YoY
Gross Margin (TTM)
47.3%β–² +1.1% YoY
Operating Income (TTM)
$1Mβ–Ό βˆ’5.8% YoY
Free Cash Flow (TTM)
$2Mβ–Ό βˆ’5.8% YoY

About APOLLOMICS INC

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
61/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Dec 2024

Latest News & Updates

BenzingaΒ·23h ago

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report

BenzingaΒ·26d ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) shares

BenzingaΒ·28d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million. Conexeu Sciences (NASDAQ:CNXU)

BenzingaΒ·Jul 13

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.

YahooΒ·Jul 13

Apollomics Regains Full Compliance with Nasdaq Listing Requirements

FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (β€œApollomics” or the β€œCompany”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement,

🌌
BenzingaΒ·Jul 13

Apollomics Regains Nasdaq Compliance

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and